The antipsychotic potential of cannabidiol: clinical implications for patients with psychosis and comorbid cannabis use disorder

The antipsychotic potential of cannabidiol: clinical implications for patients with psychosis and comorbid cannabis use disorder

J Psychiatry Neurosci January-February 2021;46(1):E164-E165 | PDF

Nicolas Garel, MD; Kyle T. Greenway MD, MSc; Ridha Joober MD, PhD


Affiliations: From McGill University, Psychiatry residency program (Garel, Greenway); and McGill University, Douglas Mental Health University Institute, (Joober), Montreal, Que., Canada.

Competing interests: R. Joober sits on the advisory boards and speakers’ bureaus of Pfizer, Janssen Ortho, BMS, Sunovion, Otsuka, Lundbeck, Perdue and Myelin; he has received grant funding from them and from AstraZeneca and HLS. He has received honoraria from Janssen Canada, Shire, Lundbeck, Otsuka, Pfizer and Perdue for CME presentations and royalties from Henry Stewart talks. He is co-editor in chief of JPN, and was not involved in the review of this manuscript or in the decision to accept it for publication. No other competing interests were declared.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is non-commercial (i.e. research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

DOI: 10.1503/jpn.200114